giant cell arteritis and tocilizumab Archives

Abstract Number: 2666 • ACR/ARP Annual Meeting 2019
Development and Outcome of Aortic Complications During Tocilizumab (TCZ) Treatment of GCA and Histopathologic Evidence of Residual Inflammation
Andrea Rubbert-Roth¹, Peter Karl Bode ², Thomas Langenegger ³, Claudia Pfofe ⁴, Thomas Neumann ⁵, Olaf Chan-Hi Kim ⁶ and Johannes von Kempis ⁷, ¹Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ²Institute of Pathology and Molecular Pathology, University Hospital of Zurich, Zuerich, Switzerland, ³Rheumatology Clinic Zug, Zug, Switzerland, ⁴Pathology Institute Triemli, Zurich, Zuerich, Switzerland, ⁵Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ⁶Department of Radiology, Kantonsspital St Gallen, St.Gallen, Switzerland, ⁷Division of Rheumatology, Kantonsspital St Gallen, St.Gallen, Switzerland
Background/Purpose: GCA may affect the aorta and lead to dissections and aortic aneurysms. TCZ treatment may control aortic inflammation as demonstrated by CRP normalization and…
Abstract Number: 2667 • ACR/ARP Annual Meeting 2019
Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience
Elena Baldissera¹, Alessandro Tomelleri ¹, Corrado Campochiaro ², Silvia Sartorelli ³ and Lorenzo Dagna ¹, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy
Background/Purpose: Tocilizumab (TCZ) has recently been shown to be effective and safe for the treatment of patients with giant cell arteritis (GCA). Here we describe…
Abstract Number: 2751 • ACR/ARHP Annual Meeting 2018
Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial
John H. Stone¹, Katie Tuckwell², Sophie Dimonaco³, Micki Klearman², Martin Aringer⁴, Daniel Blockmans⁵, Elisabeth Brouwer⁶, Maria C. Cid⁷, Bhaskar Dasgupta⁸, Juergen Rech⁹, Carlo Salvarani¹⁰, Hendrik Schulze-Koops¹¹, Georg Schett¹², Robert F. Spiera¹³, Sebastian H. Unizony¹⁴ and Neil Collinson³, ¹Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, CA, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Abteilung für Rheumatologie, Dresden, Germany, ⁵University Hospital Gasthuisberg, Leuven, Belgium, ⁶University of Groningen University Medical Center, Groningen, Netherlands, ⁷University of Barcelona, Barcelona, Spain, ⁸Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁹Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Ludwig-Maximilians-University, Munich, Germany, Munich, Germany, ¹²Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Adding tocilizumab (TCZ) to tapered prednisone treatment for patients (pts) with giant cell arteritis (GCA) leads to improved rates of sustained glucocorticoid-free remission.1 It…
Abstract Number: 2752 • ACR/ARHP Annual Meeting 2018
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Vicente Aldasoro³, Santos Castañeda⁴, Ignacio Villa-Blanco⁵, Alicia Humbría⁶, Clara Moriano Morales⁷, Susana Romero-Yuste⁸, Francisco Javier Narváez⁹, Catalina Gómez-Arango¹⁰, Eva Perez Pampín¹¹, Rafael Melero¹², Elena Becerra-Fernández¹³, Marcelino Revenga Martínez¹⁴, Noelia Álvarez-Rivas¹⁵, Carlos Galisteo¹⁶, Francisca Sivera¹⁷, Alejandro Olivé-Marqués¹⁸, Maria Concepcion Alvarez de Buergo¹⁹, Luisa Marena Rojas Vargas²⁰, Carlos Fernandez-Lopez²¹, Francisco Navarro²², Enrique Raya Álvarez²³, Eva Galindez-Agirregoikoa²⁴, Beatriz Arca²⁵, Roser Solans²⁶, Arantxa Conesa²⁷, Cristina Hidalgo-Calleja²⁸, Carlos Vázquez²⁹, Francisco Ortiz-Sanjuán³⁰, Pau Lluch³¹, Sara Manrique-Arija³², Paloma Vela³³, Eugenio De Miguel³⁴, Carmen Torres-Martín³⁵, Juan Carlos Nieto³⁶, Carmen Ordas-Calvo³⁷, Eva Salgado-Pérez³⁸, María Varela-García³⁹, Cristina Luna Gómez⁴⁰, Francisco J. Toyos Sáenz de Miera⁴¹, Nagore Fernandez-Llanio Cornella⁴², Jose Andrés Román Ivorra⁴³, Antonio García⁴⁴, Natalia Palmou-Fontana⁴⁵, Vanesa Calvo-Río⁴⁵, José Luis Martín-Varillas⁴⁵, Belén Atienza-Mateo⁴⁵, Carmen González-Vela⁴⁶, Alfonso Corrales⁴⁵, Elena Aurrecoechea⁴⁷, Raquel Dos Santos⁴⁸, Angel García-Manzanares¹³, Norberto Ortego Centeno⁴⁹, Sabela Fernández⁵⁰, Montserrat Corteguera³⁵, Miguel Angel González-Gay², José Luis Hernández² and Ricardo Blanco⁴⁵, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁴Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁷Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁸Hospital de Pontevedra. Spain, Pontevedra, Spain, ⁹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ¹⁰Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ¹¹Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹²Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹³Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, ¹⁴Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ¹⁵Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁶Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, ¹⁷Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁹Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ²⁰Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ²¹Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, ²²Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ²³Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ²⁵Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁷Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²⁸Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, ²⁹Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, ³⁰Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, ³¹Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ³²Medicine, University of Málaga, MÁLAGA, Spain, ³³Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³⁴Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ³⁵Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, ³⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁷Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ³⁸Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ³⁹Complejo Hospitalario de Navarra, Navarra, Spain, ⁴⁰Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ⁴¹Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ⁴²Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ⁴³Hospital La Fe. Valencia. Spain, Valencia, Spain, ⁴⁴Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, ⁴⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴⁸Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, ⁴⁹Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵⁰Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain
Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…
Abstract Number: 2756 • ACR/ARHP Annual Meeting 2018
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Vicente Aldasoro³, Santos Castañeda⁴, Ignacio Villa-Blanco⁵, Alicia Humbría⁶, Clara Moriano Morales⁷, Susana Romero-Yuste⁸, Francisco Javier Narváez⁹, Catalina Gómez-Arango¹⁰, Eva Perez Pampín¹¹, Rafael Melero¹², Elena Becerra-Fernández¹³, Marcelino Revenga Martínez¹⁴, Noelia Álvarez-Rivas¹⁵, Carlos Galisteo¹⁶, Francisca Sivera¹⁷, Alejandro Olivé-Marqués¹⁸, Maria Concepcion Alvarez de Buergo¹⁹, Luisa Marena Rojas Vargas²⁰, Carlos Fernandez-Lopez²¹, Francisco Navarro²², Enrique Raya Álvarez²³, Eva Galindez-Agirregoikoa²⁴, Beatriz Arca²⁵, Roser Solans²⁶, Arantxa Conesa²⁷, Cristina Hidalgo-Calleja²⁸, Carlos Vázquez²⁹, Jose Andrés Román Ivorra³⁰, Pau Lluch³¹, Sara Manrique-Arija³², Paloma Vela³³, Eugenio De Miguel³⁴, Carmen Torres-Martín³⁵, Juan Carlos Nieto³⁶, Carmen Ordas-Calvo³⁷, Eva Salgado-Pérez³⁸, Cristina Luna Gómez³⁹, Francisco J. Toyos Sáenz de Miera⁴⁰, Nagore Fernandez-Llanio Cornella⁴¹, Antonio García⁴², Carmen Larena⁴³, Belén Atienza-Mateo⁴⁴, José Luis Martín-Varillas⁴⁴, Natalia Palmou-Fontana², Vanesa Calvo-Río⁴⁴, Carmen González-Vela⁴⁵, Alfonso Corrales⁴⁴, María Varela-García⁴⁶, Elena Aurrecoechea⁴⁷, Raquel Dos Santos⁴⁸, Angel García-Manzanares¹³, Norberto Ortego Centeno⁴⁹, Sabela Fernández⁵⁰, Francisco Ortiz-Sanjuán⁵¹, Montserrat Corteguera³⁵, Miguel Angel González-Gay², José Luis Hernández² and Ricardo Blanco⁴⁴, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁴Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁷Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁸Hospital Pontevedra. Pontevedra. Spain., Pontevedra, Spain, ⁹Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ¹⁰Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ¹¹Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹²Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹³Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, ¹⁴Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ¹⁵Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁶Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, ¹⁷Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁸Hospital Trías i Pujol, Badalona, Barcelona, Spain, ¹⁹Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ²⁰Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ²¹Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, ²²Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ²³Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²⁴Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²⁵Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²⁶Systemic Autoimmune Diseases Unit, Hospital Vall d’Hebron, Barcelona, Barcelona, Spain, ²⁷Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²⁸Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, ²⁹Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, ³⁰Hospital La Fe. Valencia. Spain, Valencia, Spain, ³¹Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ³²UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain., Málaga, Spain, ³³Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³⁴Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ³⁵Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, ³⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁷Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ³⁸Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ³⁹Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ⁴⁰Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ⁴¹Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ⁴²Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, ⁴³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁶Complejo Hospitalario de Navarra, Navarra, Spain, ⁴⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴⁸Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, ⁴⁹Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵⁰Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ⁵¹Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
Abstract Number: 2757 • ACR/ARHP Annual Meeting 2018
A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Navita L. Mallalieu¹, John H. Stone², Peter M. Villiger³, Micki Klearman⁴, Laura Brockwell⁵, Sophie Dimonaco⁵ and Jean Eric Charoin⁶, ¹Roche Innovation Center, New York, NY, ²Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³University of Bern, Bern, Switzerland, ⁴Genentech, Inc., South San Francisco, CA, ⁵Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁶Roche Innovation Center (Basel), Basel, Switzerland
Background/Purpose: Tocilizumab (TCZ), an anti–interleukin-6 receptor (IL-6R) monoclonal antibody, was recently approved for the treatment of patients with giant cell arteritis (GCA) based on results…
Abstract Number: 2758 • ACR/ARHP Annual Meeting 2018
Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study
Carlotta Nannini¹, Laura Niccoli², Emanuele Antonio Maria Cassarà², Olga Kaloudi², Stelvio Sestini³ and Fabrizio Cantini², ¹Prato Hospital, Prato, Italy, ²Rheumatology, Prato Hospital, Prato, Italy, ³Radiology, Prato Hospital, Prato, Italy
Background/Purpose: The efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, in patients with refractory GCA has been demonstrated. The purpose of this study was…
Abstract Number: 816 • ACR/ARHP Annual Meeting 2017
Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
Nuria Vegas-Revenga¹, Javier Loricera¹, Antonio Mera², Eva Pérez- Pampín², Santos Castañeda³, Lucia C. Domínguez-Casas¹, José Luis Martín-Varillas⁴, Belén Atienza-Mateo⁴, MC Gonzalez-Vela¹, Jose L. Hernández⁵, Miguel Angel González-Gay⁴ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, ³Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
Abstract Number: 911 • ACR/ARHP Annual Meeting 2016
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
John H. Stone¹, Katie Tuckwell², Sophie Dimonaco², Micki Klearman³, Martin Aringer⁴, Daniel Blockmans⁵, Elisabeth Brouwer⁶, Maria C. Cid⁷, Bhaskar Dasgupta⁸, Juergen Rech⁹, Carlo Salvarani¹⁰, Robert F. Spiera¹¹, Sebastian H. Unizony¹, Neil Collinson² and the GiACTA Investigators, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Products Ltd., Welwyn Garden City, United Kingdom, ³Genentech, South San Francisco, CA, ⁴Abteilung für Rheumatologie, Dresden, Germany, ⁵General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁶Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁸Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁹Friedrich-Alexander-University Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Hospital for Special Surgery, Cornell, New York, NY
Background/Purpose: The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized,…
Abstract Number: 2104 • ACR/ARHP Annual Meeting 2016
Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis
Nekane Terrades-Garcia¹, Joana Daradoumis², Ester Planas-Rigol², Marc Corbera-Bellalta¹, Sergio Prieto-González², Georgina Espígol-Frigolé² and Maria C. Cid³, ¹Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: IL-6 has been considered a biomarker of disease activity in GCA and a potential therapeutic target. However, the functional role of IL-6 in GCA…
Abstract Number: 3142 • ACR/ARHP Annual Meeting 2015
Tocilizumab Enhances Regulatory T-Cell Activation and Proliferation in Giant Cell Arteritis
Chie Miyabe¹, Klemen Strle², Yoshishige Miyabe¹, John H. Stone^1,3, Andrew D. Luster^1,4 and Sebastian Unizony^1,5, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Charlestown, MA, ⁵Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose : CD4+ T helper (Th) 17 cells, Th1 cells, and regulatory T-cells (Treg) contribute to the pathogenesis of giant cell arteritis (GCA). Interleukin (IL)-6,…
Abstract Number: 1685 • ACR/ARHP Annual Meeting 2013
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Sebastian Unizony¹, John Stone² and Brian Keroack³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Maine Medical Center, Tufts University Medical School, Maine, ME
Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…

Abstracts tagged "giant cell arteritis and tocilizumab"